Daxas roflumilast: Additional Phase III data

Additional data from 2 double-blind, international Phase III trials (EOS and HELIOS) showed that Daxas significantly improved mean pre-bronchodilator FEV1 by 49 mL in patients treated with Serevent salmeterol vs. placebo (p<0.0001) and by 80 mL in patients

Read the full 383 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE